Shares of Pfizer (PFE) and ꧒澳洲幸运5官方开奖结果体彩网:American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmaker♊s' combined COVID-19 and flu vaccine in adults.

The companies reported that just one of two endpoints was reached in a 澳洲幸运5官方开奖结果体彩网:Phase 3 trial of the experimental treatment which used the Pfizer-BioNTech COVID-19 drug and Pfizer’s flu medicine. While positive responses to COVID-19 and influenza A viruses were seen, they were not for influenza B. 

Pfizer, BioNTech 'Evaluating Adjustments'

The companies said they are "evaluating adjustments to the candidate" and will discuss the results with health officials.

BioNTech 澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) Dr. Ugur Sahin eꦛxplained that both firms are "dedicated to developing combination vaccines which provide broader protection against multiple respiratory diseases," and that the insights gained from this trial "are highly valuable and will p🐎lay a crucial role in guiding the further development."

Included in the announcement was an update on a Phase 2 study of Pfizer's experimental second-generation trivalent influenza mRNA vaccine, which the drug maker said "showed encouraging data demonstrating robust immunogenicity against all strains compared to a standard of care influenza vaccine."

Pfizer shares, which began the day roughly flat for the year, and BioNTech ADRs slipped 1.9% and 2.9%, respectively, as of 1:30 p.m. ET Friday. BioNTech ADRs are down about 20% in 2024.